Tilray | TRLY - Interest Expense On Debt


Tilray reported $6.7M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 349.66M 12.86M Jun/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Aurora Cannabis CAD 230K 1.88M Mar/2026
Avita Medical AUD 1.25M 100K Jun/2025
Canopy Growth CAD 12.31M 4.97M Mar/2026
Cronos Group USD 0 7K Sep/2024
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Divis Laboratories Ltd INR 60M 0 Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
IQVIA Holdings USD 203M 6M Sep/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Moderna USD 10.96B 527M Jun/2026
Organigram Holdings CAD 179K 127K Mar/2025
Organon & Co USD 108M 3M Jun/2026
Revvity USD 22.99M 1.73M Jun/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Tilray USD 6.7M 2.73M Jun/2025
Viatris USD 120.7M 600K Jun/2026
Xeris Pharmaceuticals USD 6.88M 269K Mar/2026
Zealand Pharma A/S 7.07M 74K Dec/2025